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Abstract. Lung cancer is the leading cause of cancer‑associated mortality in the United States. Kinase hyperactivation is
a known mechanism of tumorigenesis. The phosphorylation
status of the plasma membrane‑associated protein myristoylated alanine rich C‑kinase substrate (MARCKS) effector
domain (ED) was previously established as being important in
the sensitivity of lung cancer to radiation. Specifically, when
MARCKS ED was in a non‑phosphorylated state, lung cancer
cells were more susceptible to ionizing radiation and experienced prolonged double‑strand DNA breaks. Additional studies
demonstrated that the phosphorylation status of MARCKS ED
is important for gene expression and in vivo tumor growth.
The present study used a peptide mimetic of MARCKS ED
as a therapeutic intervention to modulate MARCKS phosphorylation. Culturing A549, H1792 and H1975 lung cancer
cell lines with the MARCKS ED peptide led to reduced
levels of phosphorylated MARCKS and phosphorylated Akt
serine/threonine kinase 1. Further investigation demonstrated
that the peptide therapy was able to reduce lung cancer cell
proliferation and increase radiation sensitivity. In addition, the
MARCKS peptide therapy was able to prolong double‑strand
DNA breaks following ionizing radiation exposure. The
results of the present study demonstrate that a peptide mimetic
of MARCKS ED is able to modulate MARCKS phosphorylation, leading to an increase in sensitivity to radiation.
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Introduction
Lung cancer is the leading cause of cancer‑associated mortality
in the United States (1). Common molecular properties of lung
cancer include hyperactivation of receptor tyrosine kinases
(RTKs) (2). Phosphatidylinositol 3‑kinase (PI3K) is a potent
downstream RTK signaling target, which is able to phosphorylate phosphatidylinositol (4,5)‑bisphosphate (PIP2) to
generate phosphatidylinositol (3‑5)‑trisphosphate (PIP3) (3).
PIP3 recruits and activates phosphoinositide‑dependent
kinase 1 and Akt serine/threonine kinase 1 (Akt) leading to a
pro‑growth, pro‑survival phenotype (4). The plasma membrane
associated protein myristoylated alanine rich C‑kinase
substrate (MARCKS) is able to bind to PIP2, regulating the
conversion of PIP2 to PIP3 and subsequently influencing Akt
activation (5,6).
MARCKS contains three domains: An N‑terminal myristoylation domain, an MH2 domain, and an effector domain
(ED) (7). The ED of MARCKS is comprised of a 25 amino
acid sequence containing four phosphorylatable‑serine residues and 13 positively‑charged lysine residues, which allow
MARCKS to bind to the plasma membrane via electrostatic
interactions and sequester PIP2 (8‑11). The phosphorylation
status of MARCKS ED is essential in regulating the subcellular localization of MARCKS (12). Following MARCKS
ED phosphorylation, the electrostatic interaction with the
plasma membrane is lost, allowing MARCKS to migrate into
the cytoplasm, and subsequently release PIP2 (13). Following
dephosphorylation, MARCKS is able to reattach to the plasma
membrane (12).
Previously, lentiviral manipulation of A549 lung cancer
cell lines was used to overexpress a wild‑type (WT) or
non‑phosphorylatable (NP) MARCKS protein under the regulation of a tetracycline promoter. The NP‑MARCKS construct
was generated by substituting the serine residues of the ED
for alanine residues. Overexpression of NP‑MARCKS led to
increased sensitivity to radiation and prolonged double‑strand
DNA breaks following treatment with ionizing radiation (14).
MARCKS does not possess endogenous enzymatic activity
and therefore a 25 amino acid peptide mimetic of MARCKS
ED was engineered in order to modulate MARCKS
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phosphorylation (14). In the present study, the ability of
MARCKS targeted therapy to influence MARCKS phosphorylation levels and increase the sensitivity of lung cancer
cells to radiation was investigated.
Materials and methods
Cell culture. Human lung cancer cell lines A549, H1792 and
H1975 (American Type Culture Collection, Manassas, VA,
USA) were cultured in filtered (22 µm vacuum filtration; cat
no. 431097; Corning, Inc., Corning, MA, USA) RPMI‑1640
(Thermo Fisher Scientific, Inc., Waltham, MA, USA) with
10% fetal bovine serum (Sigma‑Aldrich; Merck Millipore,
Darmstadt, Germany), 1% penicillin‑streptomycin and 1%
GlutaMAX™ (Thermo Fisher Scientific, Inc.). All cells were
maintained at 37˚C in 5% CO2.
MARCKS plasmid production. A549 lung cancer cell lines were
engineered to overexpress MARCKS in a tetracycline‑dependent manner as described previously (14). WT‑MARCKS and
NP‑MARCKS sequences (GenScript USA, Inc., Piscataway,
NJ, USA) were cloned into a pLenti6.3/TO/V5 (ViraPower
HiPerform T‑REx Gateway Expression System; cat no.
A11141; Invitrogen; Thermo Fisher Scientific, Inc.) lentiviral
plasmid as described previously (5). The NP‑MARCKS was
engineered by substituting the four serine residues in the ED
to alanine residues. Exogenous MARCKS was distinguishable
from endogenous MARCKS by the addition of a V‑5 epitope
tag on the C‑terminus of WT‑ and NP‑MARCKS.
Lentiviral particle production. Lentiviral particles were
produced as described previously (14). A total of 4 µg lentiviral
packaging plasmid psPAX2 (plasmid no. 12260), lentiviral envelope plasmid PCMV‑VSV‑G (plasmid no. 8454; both Addgene,
Cambridge, Inc., MA, USA) and lentiviral vector plasmid,
were mixed with Lipofectamine® 2000 (cat no. 11668) and
Opti‑MEM™ media (cat no. 11058; both Invitrogen; Thermo
Fisher Scientific, Inc.). The lentiviral mixture was added to
the culture media of 293FT cells (Invitrogen; Thermo Fisher
Scientific, Inc.) and the media was subsequently replaced the
following morning. Lentiviral supernatant was collected after
48 h and filtered through a 0.45 µm filter, aliquoted and stored at
‑80˚C until required. Lentiviral particles were quantified using
QuickTiter p24 ELISA (Cell Biolabs, San Diego, CA, USA) (5).
Stable cell line selection. A549 cells were transduced with equal
amounts (~30 ng/ml) of p24 quantified tetracycline‑repressor
(Tet‑R) packaged lentiviral particles along with 8 µg/ml
polybrene (EMD Millipore, Billerica, MA, USA). A total of
500 µg/ml Geneticin® (cat no. G418; Thermo Fisher Scientific,
Inc.) was used to select for Tet‑R positive cells. Tet‑R cells were
subsequently transduced with equal amounts (~30 ng/ml) of
p24 quantified WT‑ and NP‑MARCKS lentiviral particles. A
total of 1 µg/ml Blastacidin (Thermo Fisher Scientific, Inc.)
was used to select for WT‑ and NP‑MARCKS‑expressing cells.
MARCKS expression was induced by culturing with 2 µg/ml of
the tetracycline homologue doxycycline overnight at 37˚C (14).
MARCKS peptide. MARCKS peptide was used as described
previously (14). MARCKS‑ED tyrosine aminotransferase
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(TAT) peptide was engineered by conjugating the cell
permeable human immunodeficiency virus (HIV) TAT
peptide via cysteine bonds to the 25 amino acid ED sequence
(KKKKKRFSFKKSFKLSGFSFKKNKK) (15). The control
peptide sequence was designed using the ExPAsy random
protein sequence generator (www.expasy.org) using the average
amino acid composition computed from Swiss‑Prot (www.
uniprot.org) (CEIEEHAWNTVEMFSSFPGTQLYNDA) to
control for peptide size. To eliminate the effect of the positive
charges, lysine and arginine residues were changed to glutamates. Peptide was added to cultures 1 h prior to performance
of in vivo assays, including immunoblotting, RNA expression
analysis, cellular survival and DNA double‑strand damage
quantification. A dose establishment study identified 6.25 µM
as the lowest effective dose (tested, 1‑25 µM), which was
selected for subsequent studies.
Immunoblotting. Immunoblotting was performed as previously described by Jarboe et al (5). Mammalian protein
extraction reagent lysis buffer supplemented with protease (cat
no. P8340; Sigma‑Aldrich; Merck Millipore) and phosphatase
inhibitors (cat nos., P0044 and P5726; Sigma‑Aldrich; Merck
Millipore) was used to lyse cells. Protein concentration was
determined by using Pierce Bicinchoninic Protein Assay
kit (Thermo Fisher Scientific, Inc.) and ~10 µg of protein
were separated via electrophoresis on an 8% SDS‑PAGE gel
and transferred to a polyvinylidene difluoride membrane
(Immobilon; Merck Millipore). Blots were blocked in
5% bovine serum albumin (BSA) (Sigma‑Aldrich; Merck
Millipore) at room temperature for 1 h and probed with the
following primary antibodies: Phosphorylated‑MARCKS
(cat no., ab81295), MARCKS (cat no., ab52616; both Abcam,
Cambridge, UK), phosphorylated‑Akt (Ser473) (cat no., D9E,
4060), Phospho‑Akt (Thr308) (cat no., C31E5E, 2965), Akt (cat
no., C67E7, 4691; all Cell Signaling Technology. Inc., Danvers,
MA, USA). Antibodies were used at a dilution of 1:1,000 with
overnight 4˚C incubation. Additionally, actin antibody (cat
no. sc‑1616; Santa Cruz Biotechnology, Inc., Dallas, TX, USA)
was used at a concentration of 1:5,000 and incubated overnight
at 4˚C. Blots were washed 3 times for 5 min in TBST. Peroxidase‑conjugated Affini Pure Goat Anti‑Mouse IgG (cat no.,
115‑035‑166) and Affini‑Pure Donkey Anti‑Rabbit IgG (cat
no. 711‑035‑152) secondary antibodies (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA) was added
at a dilution of 1:5,000 in 5% BSA‑TBST, and incubated for
1 h at room temperature. Enhanced chemiluminescence (ECL)
using Western Lighting‑Plus ECL substrate (PerkinElmer,
Inc., Waltham, MA, USA) was used to visualize the western
blots as described previously (14).
RNA expression analysis. RNA expression analysis was
performed at the UAB Nanostring Laboratory (Birmingham,
AL, USA) (www.uab.edu/medicine/radonc/en/nanostring).
The nCounter® GX Human Cancer Reference kit (NanoString
Technologies, Inc., Seattle, WA, USA) was used to analyze
RNA expression of 230 human cancer‑associated genes.
MARCKS expression in A549 NP‑MARCKS and A549
WT‑MARCKS cells was induced by overnight incubation
at 37˚C with doxycycline, and total RNA was collected the
following day. A total of 100 ng RNA was prepared in a 30 µl
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reaction volume and run on the automated nCounter system.
Quality control and normalization were performed on the raw
data using positive and negative control spots on the included
GX Human Cancer Reference Panel chip and five housekeeping reference genes (16,17).
Cell viability and survival assay. Cells were plated in black
96‑well plates (cat no. 3603; Costar; Thermo Fisher Scientific,
Inc.) and allowed to adhere overnight. The following morning
the control or ED peptides were added. A total of 1 h following
peptide treatment, cells in the irradiation group were subjected
to 0, 5 or 8 Gy irradiation using a 320 kV X‑ray irradiator
(Kimtron Inc., Woodbury, CT, USA). A total of 4 days following
peptide addition or irradiation, ATP levels were measured via
the ATPlite™ Luminescence Assay System (PerkinElmer,
Inc., Waltham, MA, USA) using a Synergy H1 Multi‑Mode
Reader (BioTek Instruments, Inc., Winooski, VT, USA).
In vivo studies. The animal protocol was provided by the
University of Alabama at Birmingham's Institutional Animal
Care and Use Committee. Mice were housed at ~24˚C
and given free access to food and water. A 12 h light/dark
schedule was provided for the mice. A total of 1 million
WT‑ or NP‑MARCKS‑expressing A549 lung cancer cells,
were injected into the flanks of ~7 week old female athymic
nude mice (~17 g) (Charles River Laboratories, Hartford, CT,
USA). Cells were mixed in a 1:1 mixture of PBS:Matrigel®
(BD Biosciences, San Jose, CA, USA) to a final volume of
50 µl and loaded into a 1 ml syringe with a 25 gx 5/8” needle
(Monoject™ Tuberculin Syringe; cat no. #8881501640;
Covidien, Dublin, Ireland) (18). When tumors were palpable,
mouse food was subsequently supplemented with doxycycline (cat no. TD.05125; Harlan Laboratories, Madison,
WI, USA) (19). WT‑ and NP‑MARCKS expression was
induced with doxycycline‑supplemented mouse food for
7 days prior to tumor volume calculation. Tumor volume
was measured using Vernier calipers using the formula:
(Length x width2)/2 (20,21). Values are presented as the mean
fold change in tumor volume ± standard error of the mean
(SEM). Mice were euthanized with CO2 inhalation as set
forth by institutional guidelines.
Double‑strand DNA damage quantification. Following overnight induction of MARCKS expression, lung cancer cells
were treated with the control or ED peptides 1 h prior to 8 Gy
irradiation. As described previously, cells were fixed and
stained with an anti‑phosphorylated‑γH2AX‑S139 antibody
and counterstained with DAPI (14). γH2AX staining foci
marking DNA double‑strand breaks were analyzed using an
EVOS FL digital inverted fluorescence microscope (Thermo
Fisher Scientific, Inc.). Positive events were defined as ≥10
foci per cell, and positive and negative controls were included
in all experiments (14,22‑24).
Statistical analysis. Statistics calculations and data graphing
was performed using GraphPad Prism (GraphPad Software,
Inc., La Jolla, CA, USA). Analysis of variance followed by
the Bonferroni correction post hoc test was used to quantify
DNA damage, and a Student's t‑test was performed to analyze
survival assays. All statistics were two‑sided and P<0.05 was

considered to indicate a statistically significant difference.
Values are presented as the mean ± SEM.
Results
Phosphorylation status of MARCKS ED influences lung
cancer biology. MARCKS ED is known to have multiple
biological functions; however, limited information is available regarding the involvement of MARCKS in lung cancer
biology (25). Reversible phosphorylation of MARCKS
ED is important in regulating the function and subcellular
localization of MARCKS (10,26). In the present study,
A549 lung cancer cells were engineered to express WT‑ or
NP‑MARCKS under the regulation of a tetracycline inducible
promoter. Western blotting (Fig. 1A) confirmed that A549
cells were able to overexpress WT‑ and NP‑MARCKS in a
tetracycline/doxycycline‑inducible manner. Due to the ability
of MARCKS to regulate multiple signaling cascades (25), the
effect of MARCKS phosphorylation on gene expression was
analyzed. Using the nCounter ® GX Human Cancer Reference kit, differences in gene expression between A549 cells
overexpressing WT‑ and NP‑MARCKS were investigated. A
total of 19 genes exhibited a >1.5 fold increase in expression
in the WT‑MARCKS cell line compared to the NP‑MARCKS
cell line, including siah E3 ubiquitin protein ligase 1, androgen
receptor, matrix metalloproteinase (MMP) 1, platelet derived
growth factor subunit A, protein tyrosine kinase 7, notch 1,
MYB proto‑oncogene, transcription factor, caspase 10, Wnt
family member 10B, MMP9, retinoic acid receptor alpha, WD
repeat domain 87, v‑myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog, B‑cell CLL/lymphoma
6, leukemia inhibitory factor, fibroblast growth factor receptor
4, S100 calcium binding protein A4, cytochrome P450 family
1 subfamily A member 1 and Fos proto‑oncogene, AP‑1 transcription factor subunit (Fig. 1B). Several of these genes are
associated with tumorigenesis and cancer progression (27‑31).
Cell viability assays were performed to investigate if the ED
phosphorylation status was important in lung cancer proliferation. The ATPlite assay indicated significantly increased
levels of ATP in the WT‑MARCKS A549 cells compared with
the NP‑MARCKS cell line (Fig. 1C; P=0.002), suggesting
that non‑phosphorylated MARCKS impedes cell viability.
In addition, in vivo mouse studies were used to assess the
ability of MARCKS ED phosphorylation status to influence
lung cancer growth. WT‑ and NP‑ MARCKS A549 cells were
injected into the flanks of athymic nude mice. Mouse food was
supplemented with doxycycline to induce the expression of
WT‑ and NP‑ MARCKS (19). The change in tumor volume
was compared between the WT‑ and NP‑MARCKS A549
cells over a period of 40 days. WT‑MARCKS transfected
mice exhibited a greater increase in tumor volume compared
with NP‑MARCKS transfected mice (Fig. 1D). By modeling
the data to a nonlinear regression fit for exponential growth,
a significant difference between the WT‑ and NP‑MARCKS
tumors (P<0.0001) was observed. The results of the present
study suggest that the phosphorylation status of MARCKS ED
influences gene expression, viability and tumor growth.
MARCKS ED provides a potential therapeutic intervention to alter lung cancer biology. Previously, a 25‑amino
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Figure 1. Phosphorylation status of MARCKS ED impacts tumorigenicity. (A) Western blot analysis of A549 lung cancer cells engineered to express WT‑ and
NP‑MARCKS under the regulation of a Doxy‑inducible promoter. A total of 2 µg/ml of Doxy was used to induce the expression of WT‑ and NP‑MARCKS.
Antibodies were used to probe for phosphorylated MARCKS, MARCKS, V5 and broad range actin. (B) The nCounter ® GX Human Cancer Reference kit
identified 19 genes that had a >1.5 fold increased expression in the WT‑MARCKS A549 cells compared with the NP‑MARCKS A549 cells. (C) ATPlite cell
viability assay measured ATP levels in WT‑ and NP‑MARCKS expressing‑A549 cells 4 days following Doxy treatment. Fluorescence levels were normalized
to A549 WT‑MARCKS cells (*P<0.05). (D) Change in tumor volume of A549 WT‑ and NP‑MARCKS expressing tumors in athymic nude mice. WT‑ and
NP‑MARCKS expression was induced with doxycycline‑supplemented mouse food for 7 days prior to tumor volume calculation. Tumor volumes were calculated over a period of 40 days. Values are presented as a linear regression of the mean ± standard error of the mean (n=9‑10; 1 mouse died unexpectedly
prior to tumor formation). MARCKS ED, myristoylated alanine rich C‑kinase substrate's effector domain; WT, wild‑type; NP, non‑phosphorylatable; Doxy,
doxycycline; P, phosphorylated.

acid peptide mimetic of MARCKS ED was used to alter
lung cancer biology (14). The 25‑amino acid ED peptide
was conjugated to the cell permeable TAT‑peptide, which
allowed the ED mimic to enter the cell. Swiss‑Prot software calculated a control peptide comprised of 25 random
amino acids to control for peptide length. The previous
investigation observed changes in cell physiology due to the
ED peptide; however, the ability of the peptide to influence
MARCKS phosphorylation or proliferation was not investigated (14). Dose titration determined that 6.25 µM was
the ideal concentration (data not shown). A549, H1792 and
H1975 lung cancer cell lines were cultured without peptide,
with 6.25 µM control peptide or with 6.25 µM ED mimetic
peptide. Western blot analysis revealed that the ED peptide
mimetic was able to decrease the level of phosphorylated
MARCKS in the three lung cancer cell lines (Fig. 2A).
Decreasing the level of phosphorylated MARCKS may
lead to increased plasma membrane‑associated MARCKS
and decreased Akt activation. Treatment of A549, and to a
lesser extent, H1975, cells with the ED‑peptide was able to
decrease levels of Akt phosphorylated at the serine 473 and
threonine 308 residues (Fig. 2A). In addition, the ED‑peptide
was able to reduce the total level of Akt, which was most

pronounced in the H1792 cells (Fig. 2A). Notably, minimal
phosphorylated T308 Akt was observed in the H1792 cells
in all conditions, though phosphorylated serine 473 Akt was
detectable and was mildly suppressed with the ED‑peptide.
The effect of MARCKS ED peptide on lung tumor growth
was investigated. ATP levels in A549, H1972 and H1975 cell
lines treated with the ED peptide mimetic were normalized to
ATP levels in lung cancer cells with no peptide intervention.
A significant decrease in ATP levels in the A549 (P= 0.045),
H1792 (P=0.000002) and H1975 (P=0.000003) lung cancer
cells following 4 days of treatment with the ED peptide was
observed compared with the control cells (Fig. 2B).
MARCKS targeted peptide increases the sensitivity of lung
cancer cells to radiation and increases γH2AX foci staining.
Previously, lentiviral manipulation was used to overexpress
NP‑MARCKS in A549 cells and their sensitivity to radiation
increased (14). In the present study, the effect of treatment
with the MARCKS ED peptide mimetic on the radiation
sensitivity of lung cancer cells was analyzed. A549, H1792
and H1975 cells were cultured with either the control or ED
peptides 1 h prior to treatment with ionizing radiation. The
three cell lines exhibited significantly decreased survival
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Figure 2. MARCKS targeted peptide therapy influences lung cancer biology. (A) A549, H1792 and H1975 lung cancer cells were cultured with no peptide,
6.25 µM control peptide, or 6.25 µM ED peptide. Western blot analysis was used to probe for phosphorylated MARCKS, MARCKS, phosphorylated Akt
(T308), phosphorylated Akt (S473), Akt and broad range actin. (B) ATPlite assay measured ATP levels 4 days following A549, H1792 and H1975 cell
transfection with no peptide, 6.25 µM control peptide, or 6.25 µM ED peptide. *P<0.05 compared with Ctrl; ***P<0.0001 compared with Ctrl. Θ indicates
treatment without peptide. MARCKS, myristoylated alanine rich C‑kinase substrate; Ctrl, control; ED, effector domain; Akt, Akt serine/threonine kinase 1;
P, phosphorylated.

following ED peptide treatment compared with the control
group at irradiation levels 0, 5 and 8 Gy (Fig. 3A; P<0.05).
DNA double‑strand breaks in A549 and H1975 cells were
examined by measuring γH2AX foci (22). γH2AX foci
increased in all groups 1 h following irradiation; however,
24 h following irradiation A549 and H1975 cells treated
with the control peptide exhibited basal level γH2AX foci
staining. Conversely, A549 and H1975 cells treated with the
ED peptide demonstrated persistent γH2AX foci staining
(Fig. 3B; P<0.01 compared with the control). The results of
the present study suggest that altering the phosphorylation
status of MARCKS ED increases lung cell sensitivity to
radiation and prolongs DNA damage following irradiation.
Discussion
MARCKS appears to have tumor suppressive properties in
glioblastoma and colon cancer (5,32), however, may function as a tumor promoter in breast and cholangiocarcinoma
cancers (33,34). The exact role MARCKS serves in cancer
biology remains unclear. The subcellular localization and
phosphorylation status of MARCKS ED are important in
the normal biological and oncogenic function and regulation of MARCKS (25,35), particularly in lung cancer (36).

Hanada et al (37) reported that squamous cell carcinoma with
increased MARCKS expression indicated poor prognosis,
however subcellular localization and phosphorylation status
were not investigated. Chen et al (38) demonstrated that
MARCKS phosphorylation is involved in invasiveness and
that lung tumors with elevated and phosphorylated MARCKS
exhibited increased invasion in vitro and in patients.
Recently, Chen et al (36) demonstrated that increased levels
of phosphorylated MARCKS are associated with decreased
patient survival and increased tumor growth. A similar
25‑amino acid peptide was used to modulate MARCKS
phosphorylation and led to reduce migration (36). Previously,
the present authors demonstrated that the phosphorylation
status of MARCKS is important in subcellular localization, drug sensitivity and the DNA damage response (14).
Specifically, lentivirally manipulated A549 lung cancer cell
lines were used and showed that NP‑MARCKS‑expressing
cells exhibited increased levels of MARCKS fluorescent
staining around the plasma membrane compared with
the WT‑MARCKS‑expressing cells, suggesting ED phosphorylation status may impact MARCKS location (14).
In the present study, A549 NP‑MARCKS‑expressing cells
exhibited increased sensitivity to radiation and prolonged
double‑strand DNA breaks, when assessed using γH2AX
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Figure 3. MARCKS targeted peptide therapy alters lung cancer response to ionizing radiation. (A) A549, H1792 and H1975 lung cancer cells were treated with
6.25 µM Ctrl peptide or 6.25 µM ED peptide 1 h prior to ionizing irradiation. A total of 4 days following irradiation ATP levels were measured. ATP levels for
each cell line were normalized to the cells treated with 0 Gy and the Ctrl peptide. (B) Cells containing >10 γH2AX staining foci were counted. A549 and H1975
cells were cultured with 6.25 µM Ctrl peptide or 6.2 5 µM ED peptide prior to 8 Gy irradiation. Time points post irradiation are indicated. *P<0.05 compared
with Ctrl; **P<0.01 compared with Ctrl; ***P<0.001 compared with Ctrl. Values shown are means derived from two independent experiments. MARCKS,
myristoylated alanine rich C‑kinase substrate; Ctrl, control; ED, effector domain; RT, radiation.

foci staining. A549 lung cancer cells are typically inherently
resistant to radiation (39). The present results demonstrated
that the phosphorylation status of MARCKS is essential
to radiation sensitivity. As MARCKS lacks endogenous
enzymatic activity, a peptide mimetic was designed to
modulate MARCKS phosphorylation. The 25‑amino acid
sequence of MARCKS ED was conjugated to the HIV TAT
peptide, which increased the ability of the peptide to enter
the cell.
In the present study, the importance of MARCKS ED
phosphorylation status in lung cancer biology was further
characterized and the therapeutic benefit of ED peptide
treatment in lung cancer was investigated. RNA expression
was observed to be altered dependent on the phosphorylation status of MARCKS in lentivirally‑engineered A549
cells. Furthermore, the phosphorylation status of MARCKS
ED in vivo was observed to impact on lung tumor growth.
The efficacy of the ED peptide was tested. Parental A549,
H1792 and H1975 lung cancer cells treated with the ED
peptide exhibited a decrease in MARCKS phosphorylation.
In addition, a decrease in T308 and S473 phosphorylation
and total Akt levels was observed. While it is unclear why
T308 phosphorylation was so low in the H1792 cells, the

ED peptide was able to decrease A549, H1792 and H1975
proliferation, and increased radiation sensitivity, though it
caused prolonged double‑strand DNA breaks only in A549
and H1975 cells following irradiation.
Lung cancer is the leading cause of cancer‑associated
mortality in the United States, and despite targeted therapy
and early detection, drug resistance frequently develops (40).
Additionally, resistance to ionizing radiation has been
observed (41). Targeting MARCKS has the potential to
provide a novel mechanism for targeting the RTK‑PI3K‑Akt
signaling cascade. The ED peptide may be able to modulate
radiation sensitivity and serve as a future method of avoiding
drug resistance (42).
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